News

BCX4208 is an oral, once-daily novel enzyme inhibitor, and is been studied as an add-on therapy to xanthine oxidase inhibitors to address unmet medical needs in patients with

Inhibitex, a biopharmaceutical company, is primarily focuses on the development of nucleotide/nucleoside analogs for the treatment of hepatitis C virus (HCV). The company’s lead HCV asset is INX-189,

The recalled Excedrin and NoDoz products have expiry dates of 20 December 2014 or earlier as while Bufferin and Gas-X Prevention products with expiry dates of 20 December

Vibativ (telavancin) for injection is Theravance’s bactericidal, once-daily lipoglycopeptide antibiotic. The rights granted to Astellas ceased upon termination of the agreement and Astellas has stopped promotional sales efforts.

Lomitapide is a small molecule microsomal triglyceride transfer protein inhibitor (MTP-I), in clinical development to examine its ability to reduce low density lipoprotein (LDL-C) or bad cholesterol levels

The trial is being funded by Galena Biopharma and Genentech/Roche through the Henry M. Jackson Foundation. Each company will provide their respective drugs for the 300 patient trial

Max is a natural energy supplement that especially combined with lean diets and fat burning workouts, providing essential nutrition, healthy energy, and long-lasting endurance for hours without side

The collaboration aims to develop simplified sample processing solutions for biothreat agents. Both the organizations will develop new solutions for efficient extraction of DNA and other nucleic acids

The process helps optimize production of a biotherapeutic in a continuous perfusion fermentation process, wherein the bioreactor (fermenter) has an ultrafiltration system that allows impurities to be removed